Skip to main content
ACR Convergence 2025 Main banner
Final Program


Schedule at a Glance
Legend
Presentation Icons
CME
CME
Non-CME
Non-CME
In Person
In Person
On Demand
On Demand
Live Stream
Live Stream
Active Learning
Active Learning
Choose Rheum
Choose Rheum
Emerging Investigator Awardee
Emerging Investigator Awardee

Irene Carrión-Barberà, MD, PhD

University of Washington
Seattle, WA, United States

Rheumatologist dedicated to systemic autoimmune diseases. During my doctoral studies, I split my time between patient care and research, being involved in multiple national research projects and clinical studies in these diseases, which has resulted in diverse publications in international journals, book chapters as well as in abstracts and oral communications in national and international conferences and congresses. Currently, I am a postdoc at the University of Washington (Seattle, USA) performing basic and translational research related to the innate immune system in systemic autoimmune diseases and vasculitis.

Presentation(s):

  • 0747: Patterns of Macrophage Polarization Induced by Serum from Patients with Giant Cell Arteritis and Takayasu’s Arteritis

    Sunday, October 26, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Eli Lilly: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Gebro: Grant/Research Support (Terminated, September 25, 2024); GlaxoSmithKlein(GSK): Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Merck/MSD: Grant/Research Support (Terminated, September 24, 2024); NordicPharma: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Otsuka: Grant/Research Support (Terminated, September 24, 2024); Sanofi: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); UCB: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024)

  • 1602: Biomarkers of Innate Immune Activation to Identify Non-Response to Rituximab in Granulomatosis with Polyangiitis

    Monday, October 27, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Eli Lilly: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Gebro: Grant/Research Support (Terminated, September 25, 2024); GlaxoSmithKlein(GSK): Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Merck/MSD: Grant/Research Support (Terminated, September 24, 2024); NordicPharma: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Otsuka: Grant/Research Support (Terminated, September 24, 2024); Sanofi: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); UCB: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024)

  • 2450: Spanish Real-World Ambispective Multicenter Registry of Anifrolumab in Systemic Lupus Erythematosus: Efficacy and Safety at 3- and 6-Month Follow-Up (ANIFRO-Reu Study)

    Tuesday, October 28, 2025
    10:30 AM - 12:30 PM Central Time

    Disclosure(s): AstraZeneca: Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Bristol-Myers Squibb(BMS): Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Eli Lilly: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Gebro: Grant/Research Support (Terminated, September 25, 2024); GlaxoSmithKlein(GSK): Consultant (Terminated, September 24, 2024), Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Janssen: Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Merck/MSD: Grant/Research Support (Terminated, September 24, 2024); NordicPharma: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); Otsuka: Grant/Research Support (Terminated, September 24, 2024); Sanofi: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024); UCB: Grant/Research Support (Terminated, September 24, 2024), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Terminated, September 24, 2024)